Komori
Sysmex (6869) · InitiativeFirst stated

Early Diagnosis of Bacterial Sepsis Using a Presepsin Assay Reagent

First written in FY2019-Q2. . Latest entry: FY2019-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Early sepsis diagnosis using a presepsin assay reagentA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019-Q2First statedAnnual report

    「In August 2018, the company launched the “HISCL™ Presepsin Reagent,” an assay reagent for presepsin, a key test marker for bacterial sepsis, for use with its fully automated immunoassay systems HISCL™-5000/2000i/800 in the immunoassay field. By adding an assay reagent for presepsin, which supports earlier and more accurate diagnosis than conventional sepsis biomarkers, to its reagent lineup, the company aims to contribute to the early diagnosis of bacterial sepsis.」

    Launched a presepsin assay reagent for use with HISCL in August 2018, demonstrating a new diagnostic application supporting earlier and more accurate diagnosis of bacterial sepsis.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sysmex yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Early Diagnosis of Bacterial Sepsis Using a Presepsin Assay Reagent | SYSMEX CORPORATION (6869) | Komori